



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Initial treatment and survival in a national unselected Danish cohort of 4163 patients with pancreatic cancer

Rasmussen, Louise Skau; Vittrup, B; Ladekarl, M.; Pfeiffer, P; Yilmaz, Mette Karen; Poulsen, Laurids Østergaard; Østerlind, K.; Skuladottir, H; Hansen, C.P.; Mortensen, M.B.; Mortensen, F.V.; Sall, Mogens; Falkmer, Ursula Gerda Inge; Fristrup, C.

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Rasmussen, L. S., Vittrup, B., Ladekarl, M., Pfeiffer, P., Yilmaz, M. K., Poulsen, L. Ø., Østerlind, K., Skuladottir, H., Hansen, C. P., Mortensen, M. B., Mortensen, F. V., Sall, M., Falkmer, U. G. I., & Fristrup, C. (2019). *Initial treatment and survival in a national unselected Danish cohort of 4163 patients with pancreatic cancer*. Poster presented at Danske Kræftforskningsdage 2019, Denmark.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.



Initial treatment and survival in a national unselected Danish cohort of 4163 patients with pancreatic cancer



L.S. Rasmussen¹, B. Vittrup², M. Ladekar³, P. Pfeiffer⁴, M.K. Yilmaz¹, L.Ø. Poulsen¹, K. Østerlind⁵, H. Skuladottir⁶, C.P. Hansen⁷, M.B. Mortensen⁸, F.V. Mortensen⁹, M. Sall¹⁰, U.G. Falkmer¹, C. Frstrup¹¹

¹Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; ²Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; ³Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; ⁴Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; ⁵Department of Oncology, Odense University Hospital, Odense, Denmark; ⁶Department of Oncology, North Sealand Hospital, Hillerød, Denmark; ⁷Department of Oncology, Herring Hospital, Herring, Denmark; ⁸Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ⁹Odense Pancreas Center (OPAC), Department of Surgery, Odense University Hospital, Odense, Denmark; ¹⁰Department of Surgical Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; ¹¹Danish Pancreatic Cancer Database; Department of Surgery, Odense University Hospital, Odense, Denmark

Background


Nationwide data on the efficacy of primary treatment on **overall survival (OS)** in an entirely unselected population of patients with pancreatic cancer (PC) have not been reported before.

Aim

To investigate the effect of initial treatment on OS in all patients with PC in Denmark diagnosed in a recent five-year period.

Material and Methods

- From 1 May 2011 to 30 April 2016, 4260 patients were identified in the national Danish Pancreatic Cancer Database (DPCD), Figure 1.
- Patients' characteristics are presented in Table 1.
- OS was analysed from the date of the initial treatment, either resection or chemotherapy or from the date of diagnosis in case of best supportive care (BSC). Last clinical follow-up was 10 September 2017.
- Treatment and clinical outcome are presented in Figure 2, Table 2 and Figure 3.



*Excluded: Preoperative/neoadjuvant chemotherapy followed by resection: 56, other malignancies: 26, incorrect registration of treatment: 13, lost to follow-up: 2.


Results

	Resection (n=718)	Chemotherapy (n=1746)	BSC (n=1699)	All (n=4163)
Age; years (median and range)	67 (13-86)	68 (34-90)	74 (24-100)	70 (13-100)
Gender				
Female	338 (47%)	813 (47%)	843 (50%)	1994 (48%)
Male	380 (53%)	933 (53%)	856 (50%)	2164 (52%)
Charlson comorbidity index				
0-2	561 (78%)	1301 (75%)	1024 (60%)	2886 (69%)
>3	157 (22%)	445 (25%)	675 (40%)	1277 (31%)
M-status*				
0	718 (100%)	905 (52%)	847 (50%)	1752 (51%)
1	0 (0%)	841 (48%)	852 (50%)	1693 (49%)
Diagnosis				
Pathology	718 (100%)	1642 (94%)	1288 (76%)	3648 (88%)
Clinical	0 (0%)	104 (6%)	411 (24%)	515 (12%)

Abbreviation: BSC: Best supportive care. *M-status: M1: patients coded with metastatic disease in DPCD within 60 days from diagnosis.


	Resection	
Lymph node metastases*	Patients No.	Median overall survival, months (95% confidence interval)
N-	215	36.9 (28.6-44.7)
N+	465	17.5 (15.4-20.1)

Abbreviations: N-: Without lymph node metastases, N+: With lymph node metastases. *38 patients without histopathological reports on lymph node status were excluded.



Treatment	Patients No.	Median overall survival, months (95% confidence interval)
Resection	718	21.9 (20.0-24.2)
Chemotherapy	1746	6.9 (6.4-7.3)
BSC*	1697	1.6 (1.5-1.7)

Abbreviation: BSC: Best supportive care. *Two patients were excluded from the survival analyses due to diagnosis date = date of death.



Regimen*	Patients No.	Median overall survival, months (95% confidence interval)
Gem monotherapy	938	5.1 (4.8-5.6)
FOLFIRINOX	435	10.0 (9.2-11.0)
GemCap	134	8.4 (6.9-9.1)
GemS1	114	8.9 (7.2-10.3)
GemPac	94	6.7 (5.5-8.7)

Abbreviations: Gem: gemcitabine, FOLFIRINOX: 5-fluorouracil, leucovorin, irinotecan and oxaliplatin, Cap: capecitabine, S1: tegafur/gimeracil/oteracil, Pac: nab-paclitaxel. *31 patients with other regimens as initial treatment than those listed were excluded.

Conclusion

- Resected lymph node negative patients had the longest survival.
- Patients initially treated with chemotherapy (mono or combination) had slightly shorter median OS than found in randomised controlled trials.
- The outcome of gemcitabine monotherapy was poor, possibly reflecting less treatment effect and selection of less fit patients.
- To reduce the group of BSC patients, new diagnostic methods are required.

